W E Whitehead1, O S Palsson, L Gangarosa, M Turner, J Tucker. 1. Center for Functional Gastrointestinal and Motility Disorders and Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, NC 27599, USA. william_whitehead@med.unc.edu
Abstract
BACKGROUND: In clinical trials, lubiprostone reduced the severity of abdominal pain. The primary aim was to determine whether lubiprostone raises the threshold for abdominal pain induced by intraluminal balloon distention. A secondary aim was to determine whether changes in pain sensitivity influence clinical pain independently of changes in transit time. METHODS:Sixty-two patients with irritable bowel syndrome with constipation (IBS-C) participated in an 8-week cross-over study. All subjects completed a 14-day baseline ending with a barostat test of pain and urge sensory thresholds. Half, randomly selected, then received 48 μg day(-1) of lubiprostone for 14 days ending with a pain sensitivity test and a Sitzmark test of transit time. This was followed by a 14-day washout and then a crossover to 14 days of placebo with tests of pain sensitivity and transit time. The other half of the subjects received placebo before lubiprostone. All kept symptom diaries. KEY RESULTS:Stools were significantly softer when taking lubiprostone compared to placebo (Bristol Stool scores 4.20 vs 3.44, P < 0.001). However, thresholds for pain (17.36 vs 17.83 mmHg, lubiprostone vs placebo) and urgency to defecate (14.14 vs 14.53 mmHg) were not affected by lubiprostone. Transit time was not significantly different between lubiprostone and placebo (51.27 vs 51.81 h), and neither pain sensitivity nor transit time was a significant predictor of clinical pain. CONCLUSIONS & INFERENCES: Lubiprostone has no effect on visceral sensory thresholds. The reductions in clinical pain that occur while taking lubiprostone appear to be secondary to changes in stool consistency.
RCT Entities:
BACKGROUND: In clinical trials, lubiprostone reduced the severity of abdominal pain. The primary aim was to determine whether lubiprostone raises the threshold for abdominal pain induced by intraluminal balloon distention. A secondary aim was to determine whether changes in pain sensitivity influence clinical pain independently of changes in transit time. METHODS: Sixty-two patients with irritable bowel syndrome with constipation (IBS-C) participated in an 8-week cross-over study. All subjects completed a 14-day baseline ending with a barostat test of pain and urge sensory thresholds. Half, randomly selected, then received 48 μg day(-1) of lubiprostone for 14 days ending with a pain sensitivity test and a Sitzmark test of transit time. This was followed by a 14-day washout and then a crossover to 14 days of placebo with tests of pain sensitivity and transit time. The other half of the subjects received placebo before lubiprostone. All kept symptom diaries. KEY RESULTS: Stools were significantly softer when taking lubiprostone compared to placebo (Bristol Stool scores 4.20 vs 3.44, P < 0.001). However, thresholds for pain (17.36 vs 17.83 mmHg, lubiprostone vs placebo) and urgency to defecate (14.14 vs 14.53 mmHg) were not affected by lubiprostone. Transit time was not significantly different between lubiprostone and placebo (51.27 vs 51.81 h), and neither pain sensitivity nor transit time was a significant predictor of clinical pain. CONCLUSIONS & INFERENCES: Lubiprostone has no effect on visceral sensory thresholds. The reductions in clinical pain that occur while taking lubiprostone appear to be secondary to changes in stool consistency.
Authors: Brennan Spiegel; Michael Camilleri; Roger Bolus; Viola Andresen; William D Chey; Sheri Fehnel; Allen Mangel; Nicholas J Talley; William E Whitehead Journal: Gastroenterology Date: 2009-08-23 Impact factor: 22.682
Authors: Michael Camilleri; Adil E Bharucha; Ryuji Ueno; Duane Burton; George M Thomforde; Kari Baxter; Sanna McKinzie; Alan R Zinsmeister Journal: Am J Physiol Gastrointest Liver Physiol Date: 2006-05 Impact factor: 4.052
Authors: Douglas A Drossman; Brenda B Toner; William E Whitehead; Nicholas E Diamant; Chris B Dalton; Susan Duncan; Shelagh Emmott; Valerie Proffitt; Donna Akman; Karen Frusciante; Terry Le; Kim Meyer; Barbara Bradshaw; Kristi Mikula; Carolyn B Morris; Carlar J Blackman; Yuming Hu; Huanguang Jia; Jim Z Li; Gary G Koch; Shrikant I Bangdiwala Journal: Gastroenterology Date: 2003-07 Impact factor: 22.682
Authors: John Cuppoletti; Danuta H Malinowska; Kirti P Tewari; Qiu-Ju Li; Ann M Sherry; Myra L Patchen; Ryuji Ueno Journal: Am J Physiol Cell Physiol Date: 2004-06-22 Impact factor: 4.249
Authors: Richard Alexander Awad; Santiago Camacho; Francisco Flores; Evelyn Altamirano; Mario Antonio García Journal: World J Gastroenterol Date: 2015-04-07 Impact factor: 5.742
Authors: Adil E Bharucha; Phillip Low; Michael Camilleri; Erica Veil; Duane Burton; Yogish Kudva; Pankaj Shah; Tonette Gehrking; Alan R Zinsmeister Journal: Gut Date: 2012-06-07 Impact factor: 23.059